Sinclair IS signs agreement with Teva

Sinclair IS Pharma has signed a license agreement with Teva Pharmaceutical Industries for Sinclair's oncology supportive care product, known as 'episil'. Under the agreement, Teva will have the exclusive commercialisation rights for episil in Germany, Spain, Poland, Switzerland and the Czech Republic. Chief executive officer of Sinclair, Chris Sponner, said: "A key part of the rationale behind the merger with IS Pharma was to broaden the sales reach of the IS portfolio through Sinclair's direct country and regional operations. This is the first in what we expect to be a number of marketing and co-marketing partnerships."Sinclair will retain an option to co-promote the product, an oral spray used for local treatment of pain associated with a serious oral side effect of chemotherapy and radiotherapy treatment, in Germany and Spain where it has its own direct sales force. Financial details of the license deal have not been released.Teva expects to launch episil in the final quarter of 2011.NR